vs

Side-by-side financial comparison of Opus Genetics, Inc. (IRD) and ReposiTrak, Inc. (TRAK). Click either name above to swap in a different company.

ReposiTrak, Inc. is the larger business by last-quarter revenue ($5.9M vs $3.9M, roughly 1.5× Opus Genetics, Inc.). On growth, ReposiTrak, Inc. posted the faster year-over-year revenue change (6.7% vs -10.2%). Over the past eight quarters, Opus Genetics, Inc.'s revenue compounded faster (50.3% CAGR vs 7.3%).

Opus Genetics, Inc. is a clinical-stage biotechnology company specializing in the development of targeted gene therapies for inherited retinal diseases. It focuses on addressing unmet medical needs for patients living with rare, vision-threatening ocular conditions, with operations centered on advancing accessible therapeutic candidates for global rare disease patient populations.

ReposiTrak, Inc. offers cloud-based supply chain management, food safety and regulatory compliance solutions for the retail, foodservice and consumer packaged goods sectors. Its platform helps clients trace products, mitigate supply chain risks, meet industry safety standards, and boost operational efficiency, with core operations focused on North American markets.

IRD vs TRAK — Head-to-Head

Bigger by revenue
TRAK
TRAK
1.5× larger
TRAK
$5.9M
$3.9M
IRD
Growing faster (revenue YoY)
TRAK
TRAK
+16.8% gap
TRAK
6.7%
-10.2%
IRD
Faster 2-yr revenue CAGR
IRD
IRD
Annualised
IRD
50.3%
7.3%
TRAK

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
IRD
IRD
TRAK
TRAK
Revenue
$3.9M
$5.9M
Net Profit
$1.7M
Gross Margin
85.4%
Operating Margin
31.0%
Net Margin
28.8%
Revenue YoY
-10.2%
6.7%
Net Profit YoY
53.0%
8.7%
EPS (diluted)
$0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IRD
IRD
TRAK
TRAK
Q4 25
$3.9M
$5.9M
Q3 25
$3.1M
$6.0M
Q2 25
$2.9M
$5.8M
Q1 25
$4.4M
$5.9M
Q4 24
$4.3M
$5.5M
Q3 24
$3.9M
$5.4M
Q2 24
$1.1M
$5.2M
Q1 24
$1.7M
$5.1M
Net Profit
IRD
IRD
TRAK
TRAK
Q4 25
$1.7M
Q3 25
$-17.5M
$1.8M
Q2 25
$-7.4M
$1.8M
Q1 25
$-8.2M
$2.0M
Q4 24
$1.6M
Q3 24
$-7.5M
$1.7M
Q2 24
$-7.8M
$1.6M
Q1 24
$-7.1M
$1.6M
Gross Margin
IRD
IRD
TRAK
TRAK
Q4 25
85.4%
Q3 25
85.7%
Q2 25
84.2%
Q1 25
84.6%
Q4 24
81.7%
Q3 24
84.2%
Q2 24
83.7%
Q1 24
83.6%
Operating Margin
IRD
IRD
TRAK
TRAK
Q4 25
31.0%
Q3 25
-269.9%
31.7%
Q2 25
-309.0%
27.5%
Q1 25
-227.2%
30.6%
Q4 24
24.6%
Q3 24
-207.1%
27.2%
Q2 24
-748.9%
25.5%
Q1 24
-450.5%
24.8%
Net Margin
IRD
IRD
TRAK
TRAK
Q4 25
28.8%
Q3 25
-566.9%
30.5%
Q2 25
-257.5%
31.2%
Q1 25
-187.5%
33.2%
Q4 24
28.2%
Q3 24
-194.6%
30.6%
Q2 24
-698.3%
30.5%
Q1 24
-415.3%
30.5%
EPS (diluted)
IRD
IRD
TRAK
TRAK
Q4 25
$0.09
Q3 25
$-0.25
$0.09
Q2 25
$-0.12
$0.09
Q1 25
$-0.24
$0.10
Q4 24
$0.08
Q3 24
$-0.29
$0.08
Q2 24
$-0.30
$0.07
Q1 24
$-0.29
$0.08

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IRD
IRD
TRAK
TRAK
Cash + ST InvestmentsLiquidity on hand
$45.1M
Total DebtLower is stronger
$170.4K
Stockholders' EquityBook value
$15.3M
$49.7M
Total Assets
$50.2M
$56.3M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IRD
IRD
TRAK
TRAK
Q4 25
$45.1M
Q3 25
$30.8M
Q2 25
$32.4M
Q1 25
$41.8M
Q4 24
$30.3M
Q3 24
$36.6M
Q2 24
$41.4M
Q1 24
$47.2M
Total Debt
IRD
IRD
TRAK
TRAK
Q4 25
$170.4K
Q3 25
$225.0K
Q2 25
$278.7K
Q1 25
$331.8K
Q4 24
$384.1K
Q3 24
$165.7K
Q2 24
$0
Q1 24
Stockholders' Equity
IRD
IRD
TRAK
TRAK
Q4 25
$15.3M
$49.7M
Q3 25
$6.0M
$50.2M
Q2 25
$17.5M
$49.5M
Q1 25
$5.1M
$48.9M
Q4 24
$6.7M
$47.9M
Q3 24
$34.3M
$47.5M
Q2 24
$40.6M
$46.9M
Q1 24
$46.1M
$46.5M
Total Assets
IRD
IRD
TRAK
TRAK
Q4 25
$50.2M
$56.3M
Q3 25
$36.1M
$55.6M
Q2 25
$38.7M
$55.3M
Q1 25
$48.2M
$54.8M
Q4 24
$36.9M
$54.7M
Q3 24
$40.4M
$52.3M
Q2 24
$44.8M
$51.6M
Q1 24
$51.8M
$51.3M
Debt / Equity
IRD
IRD
TRAK
TRAK
Q4 25
0.00×
Q3 25
0.00×
Q2 25
0.01×
Q1 25
0.01×
Q4 24
0.01×
Q3 24
0.00×
Q2 24
0.00×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IRD
IRD
TRAK
TRAK
Operating Cash FlowLast quarter
$-35.3M
$2.2M
Free Cash FlowOCF − Capex
$2.2M
FCF MarginFCF / Revenue
38.2%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
1.33×
TTM Free Cash FlowTrailing 4 quarters
$6.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IRD
IRD
TRAK
TRAK
Q4 25
$-35.3M
$2.2M
Q3 25
$-6.2M
$1.5M
Q2 25
$-10.3M
$1.7M
Q1 25
$-9.0M
$1.4M
Q4 24
$-25.6M
$3.5M
Q3 24
$-5.1M
$1.9M
Q2 24
$-7.3M
$2.1M
Q1 24
$-5.7M
$2.5M
Free Cash Flow
IRD
IRD
TRAK
TRAK
Q4 25
$2.2M
Q3 25
$1.5M
Q2 25
$1.6M
Q1 25
$1.4M
Q4 24
Q3 24
Q2 24
$2.0M
Q1 24
$2.5M
FCF Margin
IRD
IRD
TRAK
TRAK
Q4 25
38.2%
Q3 25
25.6%
Q2 25
28.6%
Q1 25
24.1%
Q4 24
Q3 24
Q2 24
38.5%
Q1 24
48.2%
Capex Intensity
IRD
IRD
TRAK
TRAK
Q4 25
0.0%
Q3 25
0.2%
Q2 25
0.1%
Q1 25
0.1%
Q4 24
0.0%
Q3 24
0.0%
Q2 24
1.1%
Q1 24
0.1%
Cash Conversion
IRD
IRD
TRAK
TRAK
Q4 25
1.33×
Q3 25
0.85×
Q2 25
0.92×
Q1 25
0.73×
Q4 24
2.23×
Q3 24
1.12×
Q2 24
1.30×
Q1 24
1.59×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IRD
IRD

Segment breakdown not available.

TRAK
TRAK

Subscription And Support$5.7M98%
Other$141.2K2%

Related Comparisons